217 related articles for article (PubMed ID: 26494583)
21. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.
Helal CJ; Kang Z; Hou X; Pandit J; Chappie TA; Humphrey JM; Marr ES; Fennell KF; Chenard LK; Fox C; Schmidt CJ; Williams RD; Chapin DS; Siuciak J; Lebel L; Menniti F; Cianfrogna J; Fonseca KR; Nelson FR; O'Connor R; MacDougall M; McDowell L; Liras S
J Med Chem; 2011 Jul; 54(13):4536-47. PubMed ID: 21650160
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.
Asproni B; Murineddu G; Pau A; Pinna GA; Langgård M; Christoffersen CT; Nielsen J; Kehler J
Bioorg Med Chem; 2011 Jan; 19(1):642-9. PubMed ID: 21087867
[TBL] [Abstract][Full Text] [Related]
23. Addressing phototoxicity observed in a novel series of biaryl derivatives: discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436.
Hamaguchi W; Masuda N; Miyamoto S; Kikuchi S; Narazaki F; Shiina Y; Seo R; Amano Y; Mihara T; Moriguchi H; Hattori K
Bioorg Med Chem; 2015 Jul; 23(13):3351-67. PubMed ID: 25960322
[TBL] [Abstract][Full Text] [Related]
24. Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.
Kawamoto Y; Tomino M; Hiramatsu K; Oyama Y; Hayashi Y
Bioorg Med Chem Lett; 2019 Jun; 29(11):1419-1422. PubMed ID: 30952590
[TBL] [Abstract][Full Text] [Related]
25. Fluorine-containing 6,7-dialkoxybiaryl-based inhibitors for phosphodiesterase 10 A: synthesis and in vitro evaluation of inhibitory potency, selectivity, and metabolism.
Schwan G; Barbar Asskar G; Höfgen N; Kubicova L; Funke U; Egerland U; Zahn M; Nieber K; Scheunemann M; Sträter N; Brust P; Briel D
ChemMedChem; 2014 Jul; 9(7):1476-87. PubMed ID: 24729456
[TBL] [Abstract][Full Text] [Related]
26. Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A.
Burdi DF; Campbell JE; Wang J; Zhao S; Zhong H; Wei J; Campbell U; Shao L; Herman L; Koch P; Jones PG; Hewitt MC
Bioorg Med Chem Lett; 2015 May; 25(9):1864-8. PubMed ID: 25863433
[TBL] [Abstract][Full Text] [Related]
27. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
Harada A; Suzuki K; Kimura H
J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
[TBL] [Abstract][Full Text] [Related]
28. Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux.
Rzasa RM; Hu E; Rumfelt S; Chen N; Andrews KL; Chmait S; Falsey JR; Zhong W; Jones AD; Porter A; Louie SW; Zhao X; Treanor JJ; Allen JR
Bioorg Med Chem Lett; 2012 Dec; 22(24):7371-5. PubMed ID: 23149228
[TBL] [Abstract][Full Text] [Related]
29. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and in vivo evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors.
Hamaguchi W; Masuda N; Samizu K; Mihara T; Takama K; Watanabe T
Chem Pharm Bull (Tokyo); 2014; 62(12):1200-13. PubMed ID: 25450629
[TBL] [Abstract][Full Text] [Related]
31. Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A).
Hu E; Chen N; Bourbeau MP; Harrington PE; Biswas K; Kunz RK; Andrews KL; Chmait S; Zhao X; Davis C; Ma J; Shi J; Lester-Zeiner D; Danao J; Able J; Cueva M; Talreja S; Kornecook T; Chen H; Porter A; Hungate R; Treanor J; Allen JR
J Med Chem; 2014 Aug; 57(15):6632-41. PubMed ID: 25062128
[TBL] [Abstract][Full Text] [Related]
32. Development of a series of novel carbon-11 labeled PDE10A inhibitors.
Stepanov V; Miura S; Takano A; Amini N; Nakao R; Hasui T; Nakashima K; Taniguchi T; Kimura H; Kuroita T; Halldin C
J Labelled Comp Radiopharm; 2015 May; 58(5):202-8. PubMed ID: 25891816
[TBL] [Abstract][Full Text] [Related]
33. Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.
Chino A; Masuda N; Amano Y; Honbou K; Mihara T; Yamazaki M; Tomishima M
Bioorg Med Chem; 2014 Jul; 22(13):3515-26. PubMed ID: 24837154
[TBL] [Abstract][Full Text] [Related]
34. Novel triazines as potent and selective phosphodiesterase 10A inhibitors.
Malamas MS; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Hage T; Ni Y; Erdei J; Fan KY; Parris K; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Brandon NJ; Hoefgen N
Bioorg Med Chem Lett; 2012 Sep; 22(18):5876-84. PubMed ID: 22902656
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part I.
Das S; Harde RL; Shelke DE; Khairatkar-Joshi N; Bajpai M; Sapalya RS; Surve HV; Gudi GS; Pattem R; Behera DB; Jadhav SB; Thomas A
Bioorg Med Chem Lett; 2014 May; 24(9):2073-8. PubMed ID: 24725435
[TBL] [Abstract][Full Text] [Related]
36. Fragment-Based Discovery of Pyrimido[1,2-b]indazole PDE10A Inhibitors.
Chino A; Seo R; Amano Y; Namatame I; Hamaguchi W; Honbou K; Mihara T; Yamazaki M; Tomishima M; Masuda N
Chem Pharm Bull (Tokyo); 2018; 66(3):286-294. PubMed ID: 29491261
[TBL] [Abstract][Full Text] [Related]
37. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
Vlasceanu A; Jessing M; Kilburn JP
Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
[TBL] [Abstract][Full Text] [Related]
38. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Raheem IT; Schreier JD; Fuerst J; Gantert L; Hostetler ED; Huszar S; Joshi A; Kandebo M; Kim SH; Li J; Ma B; McGaughey G; Sharma S; Shipe WD; Uslaner J; Vandeveer GH; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
Bioorg Med Chem Lett; 2016 Jan; 26(1):126-32. PubMed ID: 26602277
[TBL] [Abstract][Full Text] [Related]
39. Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors.
Hu E; Kunz RK; Rumfelt S; Chen N; Bürli R; Li C; Andrews KL; Zhang J; Chmait S; Kogan J; Lindstrom M; Hitchcock SA; Treanor J
Bioorg Med Chem Lett; 2012 Mar; 22(6):2262-5. PubMed ID: 22365755
[TBL] [Abstract][Full Text] [Related]
40. Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.
Wagner S; Scheunemann M; Dipper K; Egerland U; Hoefgen N; Steinbach J; Brust P
Eur J Med Chem; 2016 Jan; 107():97-108. PubMed ID: 26562545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
